AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30383486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3) 2,000 IU daily
Number of subjects: 100
Study 30383486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3) 3,000 IU daily
Number of subjects: 100
Study 30383486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol (D2) 50,000 IU weekly
Number of subjects: 100
Study 30383486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol (D2) 50,000 IU twice weekly
Number of subjects: 100
Study 27806644 — intervention group
Group type: EXPERIMENTAL
Intervention: F(ab')2 with maintenance
Number of subjects: 122
Study 27806644 — intervention group
Group type: COMPARATOR
Intervention: F(ab')2 with placebo maintenance
Number of subjects: 122
Study 27806644 — intervention group
Group type: EXPERIMENTAL
Intervention: Fab with maintenance
Number of subjects: 122
Study 25296727 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite physical activity intervention (AME for Activity)
Number of subjects: 1260
Study 24263123 — intervention group
Group type: COMPARATOR
Intervention: L‐NMMA in healthy control subjects (CON)
Number of subjects: 22
Study 24263123 — intervention group
Group type: COMPARATOR
Intervention: L‐NMMA in patients with CHF
Number of subjects: 22
Study 21771174 — intervention group
Group type: EXPERIMENTAL
Intervention: The perioperative dialogue (PD)
Number of subjects: 93
Study 21771174 — intervention group
Group type: COMPARATOR
Intervention: Standard perioperative care (control group)
Number of subjects: 93
Study 18997085 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MacTel type 2
Number of subjects: 26
Study 18997085 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (age-matched normal subjects)
Number of subjects: 26
Study 16426096 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 4417
Study 16426096 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 4417
Study 16426096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4417
Study 14991636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 40
Study 14991636 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 40
Study 11506841 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic catheter
Number of subjects: 90
Study 11506841 — intervention group
Group type: COMPARATOR
Intervention: Microtransducer catheter
Number of subjects: 90
Study 9209198 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progesterone plus calcium
Number of subjects: 236
Study 9209198 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 236
Study 8427434 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg single-dose IM injection)
Number of subjects: 58
Study 8427434 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline IM injection)
Number of subjects: 58
Study 8427434 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 58
Study 8427434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 2831320 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid (4 g daily safflower seed oil)
Number of subjects: 13
Study 30514795 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Survivorship Care Plans (SCPs)
Number of subjects: 495
Study 30514795 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 495
Study 28744821 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed instruction
Number of subjects: 80
Study 28744821 — intervention group
Group type: COMPARATOR
Intervention: Massed instruction
Number of subjects: 80
Study 28744821 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked practice
Number of subjects: 80
Study 28744821 — intervention group
Group type: COMPARATOR
Intervention: Mixed practice
Number of subjects: 80
Study 26766754 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Speaks intervention (one-hour performance followed by discussion)
Number of subjects: 27
Study 26766754 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 27
Study 23899828 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (aerobic exercise three times per week for 12 weeks)
Number of subjects: 248
Study 23899828 — intervention group
Group type: COMPARATOR
Intervention: Usual activity (control group)
Number of subjects: 248
Study 22879677 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltoid, triceps, or both twitches (Group DT)
Number of subjects: 300
Study 22879677 — intervention group
Group type: COMPARATOR
Intervention: Biceps twitches (Group B)
Number of subjects: 300
Study 19548448 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive acupoints thread embedding (IATE) at Dachangshu (BL 25), Tianshu (ST 25), Zhongji (CV 3), and Zusanli (ST 36) for STC patients (62 patients)
Number of subjects: 310
Study 19548448 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive acupoints thread embedding (IATE) at the same acupoints and local anal operation for MC patients (62 patients)
Number of subjects: 310
Study 19548448 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Simo Decoction for STC patients in control group I (62 patients)
Number of subjects: 310
Study 19548448 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Simo Decoction for MC patients in control group II (62 patients)
Number of subjects: 310
Study 19548448 — intervention group
Group type: COMPARATOR
Intervention: Local anal operation alone for MC patients in control group III (62 patients)
Number of subjects: 310
Study 17884516 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 sterile surgical gloves
Number of subjects: 42
Study 17884516 — intervention group
Group type: COMPARATOR
Intervention: nonsterile disposable inner glove under a sterile surgical glove
Number of subjects: 42
Study 17884516 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 42
Study 15127082 — intervention group
Group type: EXPERIMENTAL
Intervention: citalopram (20 mg)
Number of subjects: 15
Study 15127082 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram (10 mg)
Number of subjects: 15
Study 15127082 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 12173168 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster Pain Intervention (FPI)
Number of subjects: 70
Study 12173168 — intervention group
Group type: COMPARATOR
Intervention: Routine information through videotaped instruction (Control)
Number of subjects: 70
Study 10093686 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte macrophage colony stimulating factor (GM-CSF)
Number of subjects: 117
Study 10093686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 7587035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 2 g every 12 h
Number of subjects: 0
Study 7587035 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 4 g once daily
Number of subjects: 0
Study 7587035 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g every 12 h
Number of subjects: 0
Study 2378239 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil + 67% N2O + 33% O2
Number of subjects: 74
Study 2378239 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil + 67% N2O + 33% O2 + droperidol 0.015 mg/kg
Number of subjects: 74
Study 2378239 — intervention group
Group type: COMPARATOR
Intervention: alfentanil + 100% O2 + 0.7% isoflurane
Number of subjects: 74
Study 2378239 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (alfentanil + 67% N2O + 33% O2)
Number of subjects: 74
Study 2378239 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (alfentanil + 67% N2O + 33% O2 + droperidol 0.015 mg/kg)
Number of subjects: 74
Study 2378239 — intervention group
Group type: COMPARATOR
Intervention: Group III (alfentanil + 100% O2 + 0.7% isoflurane)
Number of subjects: 74
Study 489767 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg indoprofen
Number of subjects: 0
Study 489767 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg indoprofen
Number of subjects: 0
Study 489767 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg aspirin
Number of subjects: 0
Study 489767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30845817 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/day
Number of subjects: 480
Study 30845817 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3.0 mg/day
Number of subjects: 480
Study 30845817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 27807948 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable everolimus‐eluting scaffolds (BVS)
Number of subjects: 200
Study 27807948 — intervention group
Group type: COMPARATOR
Intervention: Pt‐Cr everolimus‐eluting stent with abluminal bioabsorbable polymer (Synergy)
Number of subjects: 200
Study 26241349 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 kilocalories per kilogram of body weight per week (KKW) for 12 weeks
Number of subjects: 0
Study 26241349 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 KKW for 12 weeks
Number of subjects: 0
Study 26241349 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 23657862 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight mesh (LWM)
Number of subjects: 0
Study 23657862 — intervention group
Group type: COMPARATOR
Intervention: Heavyweight mesh (HWM)
Number of subjects: 0
Study 23657862 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 22879808 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal workshop in EBM literature searching skills
Number of subjects: 121
Study 19090446 — intervention group
Group type: EXPERIMENTAL
Intervention: Low threshold intervention consisting of an age-adapted nutrition and exercise program
Number of subjects: 365
Study 19090446 — intervention group
Group type: COMPARATOR
Intervention: Low threshold intervention (non-participants)
Number of subjects: 365
Study 19090446 — intervention group
Group type: COMPARATOR
Intervention: Control group (not informed children)
Number of subjects: 365
Study 17288692 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 201
Study 17288692 — intervention group
Group type: COMPARATOR
Intervention: Standard Current Therapy (SCT)
Number of subjects: 201
Study 15450616 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick-change method
Number of subjects: 30
Study 15450616 — intervention group
Group type: EXPERIMENTAL
Intervention: Double infusion method
Number of subjects: 30
Study 11868687 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led weaning from mechanical ventilation
Number of subjects: 3
Study 11868687 — intervention group
Group type: COMPARATOR
Intervention: Doctor-led care (Control)
Number of subjects: 3
Study 9492772 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 600 mg twice daily (n = 543)
Number of subjects: 1090
Study 9492772 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 547)
Number of subjects: 1090
Study 8288782 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin (20 to 30 mg/day for 16 weeks)
Number of subjects: 78
Study 8288782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 2205115 — intervention group
Group type: EXPERIMENTAL
Intervention: doxepin hydrochloride, up to 150 mg/day
Number of subjects: 15
Study 2205115 — intervention group
Group type: COMPARATOR
Intervention: inert medication
Number of subjects: 15
Study 198914 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage grouping modification suggested by the Radiation Therapy Oncology Group
Number of subjects: 403
Study 198914 — intervention group
Group type: COMPARATOR
Intervention: Joint Committee classification
Number of subjects: 403
Study 198914 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection of small peripheral lesions without metastatic lymph node involvement
Number of subjects: 403
Study 30666827 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg
Number of subjects: 18
Study 30666827 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg
Number of subjects: 18
Study 30666827 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 18
Study 29082858 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided ACTonPain
Number of subjects: 302
Study 29082858 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided ACTonPain
Number of subjects: 302
Study 29082858 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 302
Study 24815199 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 0.15 mg/kg
Number of subjects: 288
Study 24815199 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 0.30 mg/kg
Number of subjects: 288
Study 24815199 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 0.30 mg/kg with ≥ 150 mg/day baseline morphine equivalent doses
Number of subjects: 288
Study 24815199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 24815199 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled Methylnaltrexone
Number of subjects: 288
Study 23098281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 184
Study 23098281 — intervention group
Group type: COMPARATOR
Intervention: 3-dimensional conformal radiotherapy (3DCRT)
Number of subjects: 184
Study 21596189 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative patient‐controlled epidural analgesia (PCEA) with continuous infusion of ropivacaine and fentanyl (Group I)
Number of subjects: 38
Study 21596189 — intervention group
Group type: COMPARATOR
Intervention: Postoperative patient‐controlled continuous wound catheter infusion of ropivacaine (Group II)
Number of subjects: 38
Study 19884547 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening intervention
Number of subjects: 8
Study 18823218 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole oral suspension 200 mg 3 times/day with meals or a nutritional supplement for a minimum of 7 days to achieve steady state and for a maximum of 12 weeks.
Number of subjects: 194
Study 18823218 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole oral suspension 200 mg 3 times/day
Number of subjects: 194
Study 18823218 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 194
Study 18823218 — intervention group
Group type: COMPARATOR
Intervention: Standard azoles (fluconazole and itraconazole)
Number of subjects: 194
Study 15114082 — intervention group
Group type: EXPERIMENTAL
Intervention: Celsior solution
Number of subjects: 105
Study 15114082 — intervention group
Group type: COMPARATOR
Intervention: University of Wisconsin (UW) solution
Number of subjects: 105
Study 11179517 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban plus heparin
Number of subjects: 834
Study 11179517 — intervention group
Group type: COMPARATOR
Intervention: heparin alone
Number of subjects: 834
Study 9484194 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth-year student preceptors
Number of subjects: 93
Study 9484194 — intervention group
Group type: COMPARATOR
Intervention: Faculty preceptors
Number of subjects: 93
Study 8275477 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 182780 (6 mg)
Number of subjects: 56
Study 8275477 — intervention group
Group type: COMPARATOR
Intervention: Control (no preoperative treatment)
Number of subjects: 56
Study 3178925 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg acetylsalicylic acid (ASA)
Number of subjects: 12
Study 3178925 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg paracetamol
Number of subjects: 12
Study 3178925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31708998 — intervention group
Group type: COMPARATOR
Intervention: 2-phase pattern
Number of subjects: 10
Study 31708998 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant-derived pattern
Number of subjects: 10
Study 29340354 — intervention group
Group type: EXPERIMENTAL
Intervention: Four immediately loaded mini dental implants (MDIs)
Number of subjects: 50
Study 29340354 — intervention group
Group type: COMPARATOR
Intervention: Two standard‐sized interconnected implants (STL)
Number of subjects: 50
Study 29340354 — intervention group
Group type: EXPERIMENTAL
Intervention: Four MDIs
Number of subjects: 50
Study 29340354 — intervention group
Group type: COMPARATOR
Intervention: Two STL implants
Number of subjects: 50
Study 26630974 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K1 ≥ 0.76 and 25(OH)D ≥ 50 nmol/l
Number of subjects: 21774
Study 26630974 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K1 ≥ 0.76 and 25(OH)D < 50 nmol/l
Number of subjects: 21774
Study 26630974 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K1 < 0.76 and 25(OH)D ≥ 50 nmol/l
Number of subjects: 21774
Study 26630974 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K1 < 0.76 and 25(OH)D < 50 nmol/l
Number of subjects: 21774
Study 24131095 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal radiofrequency (RF) prior to hyaluronic acid (HA) filler
Number of subjects: 10
Study 24131095 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) filler alone
Number of subjects: 10
Study 22814178 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 80
Study 22814178 — intervention group
Group type: COMPARATOR
Intervention: Non-RAAS regimen
Number of subjects: 80
Study 22814178 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 80
Study 22814178 — intervention group
Group type: COMPARATOR
Intervention: Non-RAAS
Number of subjects: 80
Study 20659545 — intervention group
Group type: EXPERIMENTAL
Intervention: GBQDYS decoction
Number of subjects: 68
Study 20659545 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 17980273 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA) with shunting, patching, and intraoperative completion duplex ultrasound imaging
Number of subjects: 391
Study 15736522 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Gamble (SG)
Number of subjects: 50
Study 15736522 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 50
Study 15736522 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergent validity assessment
Number of subjects: 50
Study 11835456 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular botulinum toxin type A (BT‐A) with electrical stimulation (Group A, n = 6)
Number of subjects: 12
Study 11835456 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular botulinum toxin type A (BT‐A) alone (Group B, n = 6)
Number of subjects: 12
Study 9653480 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 46
Study 9653480 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 46
Study 9653480 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser
Number of subjects: 46
Study 8137977 — intervention group
Group type: EXPERIMENTAL
Intervention: Coculture on Vero cells
Number of subjects: 16
Study 8137977 — intervention group
Group type: COMPARATOR
Intervention: Routine embryo culture medium
Number of subjects: 16
Study 2590625 — intervention group
Group type: EXPERIMENTAL
Intervention: Coal tar gel
Number of subjects: 45
Study 2590625 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroid
Number of subjects: 45
Study 5473608 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolyte solution containing both glucose and glycine
Number of subjects: 0
Study 5473608 — intervention group
Group type: COMPARATOR
Intervention: Electrolyte solution containing glucose
Number of subjects: 0
Study 5473608 — intervention group
Group type: COMPARATOR
Intervention: Electrolyte solution containing glycine
Number of subjects: 0
Study 30798376 — intervention group
Group type: EXPERIMENTAL
Intervention: PMTCT intervention with male partner involvement
Number of subjects: 1370
Study 30798376 — intervention group
Group type: COMPARATOR
Intervention: PMTCT intervention without male partner involvement
Number of subjects: 1370
Study 30798376 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1370
Study 31200633 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+
Number of subjects: 71
Study 31200633 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 71
Study 29236273 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory brainstem response (ABR) presence
Number of subjects: 60
Study 29236273 — intervention group
Group type: EXPERIMENTAL
Intervention: No recorded wave of ABR
Number of subjects: 60
Study 29236273 — intervention group
Group type: EXPERIMENTAL
Intervention: Distortion‐product OAE (DP‐OAE)
Number of subjects: 60
Study 25481673 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI-B (bevacizumab plus FOLFIRI)
Number of subjects: 142
Study 25481673 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI alone
Number of subjects: 142
Study 24247812 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL 200 mg once daily
Number of subjects: 27
Study 24247812 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol IR 50 mg four times daily
Number of subjects: 27
Study 24247812 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol IR 100 mg twice daily
Number of subjects: 27
Study 21926663 — intervention group
Group type: EXPERIMENTAL
Intervention: Washed red blood cells and platelets transfusion
Number of subjects: 162
Study 21926663 — intervention group
Group type: COMPARATOR
Intervention: Unwashed red blood cells and platelets transfusion
Number of subjects: 162
Study 19953917 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal‐LMA
Number of subjects: 60
Study 19953917 — intervention group
Group type: COMPARATOR
Intervention: Normal endotracheal tube
Number of subjects: 60
Study 17296533 — intervention group
Group type: EXPERIMENTAL
Intervention: Steatosis scores of 0-2 among nondiabetic patients
Number of subjects: 1143
Study 17296533 — intervention group
Group type: EXPERIMENTAL
Intervention: Steatosis scores of 3-4 among nondiabetic patients
Number of subjects: 1143
Study 17296533 — intervention group
Group type: EXPERIMENTAL
Intervention: Steatosis scores of 2-4 among nondiabetic patients
Number of subjects: 1143